Global Neuroendocrine Tumor Treatment Market

The Neuroendocrine Tumor Treatment Market size was valued at USD 1.99 Billion in 2025 and the total Neuroendocrine Tumor Treatment revenue is expected to grow at a CAGR of 10.11% from 2025 to 2032, reaching nearly USD 3.91 Billion by 2032.

Neuroendocrine Tumor Treatment Market Overview:

The improper growth of neoplasms that arise from cells of the numerous endocrine glands and neurological systems causes neuroendocrine tumours. These are commonly called carcinoid tumours because they get infected first in the intestine.
To know about the Research Methodology :- Request Free Sample Report

Neuroendocrine Tumor Treatment Market Dynamics:

Increasing prevalence of Neuroendocrine Tumor is expected to propel the market growth.

Increased incidences of neuroendocrine tumours (NETs) are predicted to boost demand for treatment options, boosting the market growth during the forecast period. Novel therapeutics and diagnostic products are being developed at a rapid pace in this field. Neurofibromatosis type 1 (NF1), Multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), Von Hippel- tuberous sclerosis complex (TSC) and Lindau syndrome (VHL) disease are all increasing the incidence and prevalence of neuroendocrine tumours (NETs) in the United States. Furthermore, according to a study published in the JAMA Oncology Journal in 2017, the survival rate of all neuroendocrine tumour treatments have improved, particularly in the treatment of distant-stage gastrointestinal neuroendocrine tumours and pancreatic neuroendocrine tumours. This is mostly due to the availability of effective medicines and early disease detection.

The market for neuroendocrine tumour treatment is predicted to grow due to the development of new medications. Cancer can be treated in a variety of ways. One of the most popular treatment options for neuroendocrine tumours is targeted therapy. Cancer treatment that uses targeted therapy is quite effective. As a result, targeted NET therapies are predicted to become more popular in the forecast years. Over the forecast period, the market is expected to grow due to an increase in the number of pharmacological approvals for the treatment of neuroendocrine tumours. For example, in January 2018, Novartis Groupe S.A.'s Advanced Accelerator Applications received FDA approval of its new drug application (NDA) for Lutathera for the treatment of Somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), which include foregut, midgut, and hindgut neuroendocrine tumours.

The report has profiled eighteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Neuroendocrine Tumor Treatment Market Segment Analysis:

The Global Neuroendocrine Tumor Treatment Market is segmented on the basis of Product, Indication and End-users.

Based on Product, the Somatostanin Analogs segment is expected to dominate the global market during the forecast period. Somatostanin Analogs (SSAs) are the most commonly utilized medications to treat neuroendocrine carcinoma because they reduce cancer growth, symptoms, and target biomarkers. Because of the safe treatment procedures provided by SSAs, they account for the biggest revenue share. SSAs are commonly utilized to treat patients who have failed to respond to radiation therapy or surgery. As a result, many SSAs are now in clinical trials and awaiting clearance, and the market is likely to grow rapidly over the forecast period. Tarveda Therapeutics' PEN-221 and Dauntless Pharmaceuticals' DP1038 are two examples. Drugs like Sunitinib and Everolimus are used in targeted therapy. These medications are used as the first line of therapy for neuroendocrine carcinoma since they have less negative effects. Chemotherapy, radiation therapy, surgery, and tyrosine kinase inhibitors are among the additional products available.

Based on Indication, the gastrointestinal segment accounted for the dominant segment in 2021 as NETs are more likely to arise in the GI tract. According to data provided in a Novartis investor presentation in 2015, GI tumours account for 61% of all NETs, with the small intestine tumour being the most common. According to the American Society of Clinical Oncology (ASCO), roughly 8,000 persons in the United States have diagnosed with GI tract-carcinid tumours in 2017. Over the projected period, the rising occurrence of carcinoid tumours in the GI tract is expected to propel the segment forward.

Neuroendocrine Tumor Treatment Market Regional Insights:

North America is expected to dominate the global market throughout the forecast period.

Because of the increased frequency of neuroendocrine illnesses, developed health care infrastructure, strong clinical pipeline, high level of awareness among individuals, and presence of significant market participants, North America dominates the neuroendocrine tumours market. In this area, there are also supporting insurance programmes, such as Medicare, Medicaid, and Tricare, which make neuroendocrine treatment grow during forecast years. For example, Ipsen got FDA clearance for its Somatuline Depot (lanreotide) Injection 120 mg in December 2014, which is approved for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally progressed or metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

In addition, the European neuroendocrine tumour therapy market is predicted to grow significantly over the forecast period, owing to an increase in product approvals by the European Commission (EC) for marketing in European countries.

The report also helps in understanding Global Neuroendocrine Tumor Treatment Market dynamics, structure by analyzing the market segments and project the Global Neuroendocrine Tumor Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Neuroendocrine Tumor Treatment Market make the report investor’s guide.

Global Neuroendocrine Tumor Treatment Market Scope: Inquire before buying

Neuroendocrine Tumor Treatment Market, by Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Neuroendocrine Tumor Treatment Market, Key Players are:

1.Novartis AG
2.Boehringer Ingelheim International GmbH
3.Pfizer, Inc.
4.Ipsen Pharma
5.AVEO Oncology
6.Hutchison MediPharma Limited
7.Progenics Pharmaceuticals
8.F. Hoffmann-La Roche Ltd
9.Bristol-Myers Squibb Company
10.Viatris Inc.
11.Thermo Fisher Scientific Inc.
12.Regeneron Pharmaceuticals, Inc.
13.Sun Pharmaceutical Industries Ltd.
14.Teva Pharmaceutical Industries Ltd.
15.Eli Lilly and Company
16.LUPIN
17.Advanced Accelerator Applications
18.BioSynthema Inc.

Frequently Asked questions

1. What is the market size of the Global Neuroendocrine Tumor Treatment Market in 2025?
Ans. The market size Global Neuroendocrine Tumor Treatment Market in 2025 was USD 1.99 Billion.

2. What are the different segments of the Global Neuroendocrine Tumor Treatment Market?
Ans. The Global Neuroendocrine Tumor Treatment Market is divided into Product, Application and Type.

3. What is the study period of this market?
Ans. The Global Neuroendocrine Tumor Treatment Market will be studied from 2025 to 2032.

4. Which region is expected to hold the highest Global Neuroendocrine Tumor Treatment Market share?
Ans. The Asia Pacific dominates the market share in the  market.

5. What  is the Forecast Period of Global Neuroendocrine Tumor Treatment Market?
Ans. The Forecast Period of the market is 2026-2032 in the market.